This summary module provides a high-level review of the groundbreaking clinical updates and technological advancements presented at the 86th ADA Scientific Sessions in New Orleans. The curriculum highlights key research, including the efficacy of novel triple agonist therapies like retatrutide for weight and A1c management, alongside major shifts in diabetes technology. Participants will explore data on the expanded use of continuous glucose monitoring (CGM) in non-insulin-treated type 2 diabetes, the advent of dual glucose-ketone sensors for DKA risk detection, and performance benchmarks for next-generation automated insulin delivery (AID) systems.